These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37781962)

  • 1. Head-to-head comparison of three chelates reveals DOTAGA promising for
    Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
    Cancer Sci; 2023 Dec; 114(12):4677-4690. PubMed ID: 37781962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FZD10-targeted α-radioimmunotherapy with
    Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
    Cancer Sci; 2022 Feb; 113(2):721-732. PubMed ID: 34935247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.
    Li HK; Sugyo A; Tsuji AB; Morokoshi Y; Minegishi K; Nagatsu K; Kanda H; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T; Hasegawa S
    Cancer Sci; 2018 Jul; 109(7):2302-2309. PubMed ID: 29952132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bifunctional chelates for (64)Cu antibody imaging.
    Ferreira CL; Yapp DT; Crisp S; Sutherland BW; Ng SS; Gleave M; Bensimon C; Jurek P; Kiefer GE
    Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2117-26. PubMed ID: 20552190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.
    Sarrut D; Badel JN; Halty A; Garin G; Perol D; Cassier P; Blay JY; Kryza D; Giraudet AL
    EJNMMI Phys; 2017 Dec; 4(1):6. PubMed ID: 28101733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.
    Ait-Mohand S; Fournier P; Dumulon-Perreault V; Kiefer GE; Jurek P; Ferreira CL; Bénard F; Guérin B
    Bioconjug Chem; 2011 Aug; 22(8):1729-35. PubMed ID: 21761921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M; Vaidyanathan G; Welsh P; Zalutsky MR
    Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
    Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
    J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.
    Yang CT; Kim YS; Wang J; Wang L; Shi J; Li ZB; Chen X; Fan M; Li JJ; Liu S
    Bioconjug Chem; 2008 Oct; 19(10):2008-22. PubMed ID: 18763821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.
    Moreau M; Raguin O; Vrigneaud JM; Collin B; Bernhard C; Tizon X; Boschetti F; Duchamp O; Brunotte F; Denat F
    Bioconjug Chem; 2012 Jun; 23(6):1181-8. PubMed ID: 22519915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
    Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M
    Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
    Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.